International Journal of Inflammation

International Journal of Inflammation / 2020 / Article

Corrigendum | Open Access

Volume 2020 |Article ID 3503814 | https://doi.org/10.1155/2020/3503814

Weiling Leng, Xiaotian Lei, Hao Meng, Xinshou Ouyang, Ziwen Liang, "Corrigendum to “EOLA1 Inhibits Lipopolysaccharide-Induced Vascular Cell Adhesion Molecule-1 Expression by Association with MT2A in ECV304 Cells”", International Journal of Inflammation, vol. 2020, Article ID 3503814, 1 page, 2020. https://doi.org/10.1155/2020/3503814

Corrigendum to “EOLA1 Inhibits Lipopolysaccharide-Induced Vascular Cell Adhesion Molecule-1 Expression by Association with MT2A in ECV304 Cells”

Received06 Aug 2020
Accepted06 Aug 2020
Published27 Sep 2020

In the article titled “EOLA1 inhibits lipopolysaccharide-induced vascular cell adhesion molecule-1 expression by association with MT2A in ECV304 cells” [1], the ECV-304 cell line has been found to be cross-contaminated by T-24, which is a bladder carcinoma cell line [2, 3].

References

  1. W. Leng, X. Lei, H. Meng, X. Ouyang, and Z. Liang, “EOLA1 inhibits lipopolysaccharide-induced vascular cell adhesion molecule-1 expression by association with MT2A in ECV304 cells,” International Journal of Inflammation, vol. 2015, Article ID 301562, 8 pages, 2015. View at: Publisher Site | Google Scholar
  2. http://iclac.org/databases/cross-contaminations/.
  3. A. Capes-Davis, G. Theodosopoulos, I. Atkin et al., “Check your cultures! A list of cross-contaminated or misidentified cell lines,” International Journal of Cancer, vol. 127, no. 1, pp. 1–8, 2010. View at: Publisher Site | Google Scholar

Copyright © 2020 Weiling Leng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views52
Downloads42
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.